Foghorn Therapeutics (FHTX) Change in Accured Expenses (2019 - 2026)

Foghorn Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 85.21% year-over-year to -$4.5 million in Q1 2026; TTM through Mar 2026 was $153000.0, a 193.87% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, up 490.78% from the prior year.
• Change in Accured Expenses eased to -$4.5 million in Q1 2026 per FHTX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.0 million in Q3 2024 and bottomed at -$4.5 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $332000.0 (2023), against an average of -$186705.9.
• Across the five-year window, Change in Accured Expenses sank 829.22% in 2024 and soared 764.14% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $894000.0 in 2022, then plunged by 62.86% to $332000.0 in 2023, then sank by 829.22% to -$2.4 million in 2024, then soared by 159.27% to $1.4 million in 2025, then plunged by 410.66% to -$4.5 million in 2026.
• Per Business Quant, the three latest FHTX Change in Accured Expenses figures stand at -$4.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.2 million (Q3 2025).